Beyond CIN, other genetic and epigenetic alterations—such as loss-of-function mutations in STING or cGAS, promoter hypermethylation [106], or overexpression of DNA exonucleases like TREX1 [107]—may also diminish the efficacy of STING agonists. This evidence concerns the gene STING1 and cervical squamous intraepithelial neoplasia.